[Rapid response to mepolizumab in Wells syndrome despite absence of blood eosinophilia or other eosinophilic disorders].

Authors

Finn Abeck, I Hansen-Abeck, F Ohm, U Siemann-Harms, N Booken, S W Schneider

Published in

Dermatologie (Heidelberg, Germany). Jul 27, 2026. Epub Jul 27, 2026.

Abstract

Wells syndrome is a rare eosinophilic dermatosis that is commonly treated with systemic corticosteroids. We report the successful use of the anti-interleukin‑5 antibody mepolizumab in a 76-year-old woman with Wells syndrome. This case demonstrates that mepolizumab may represent an effective treatment option after failure of standard therapies. Its use should also be considered in the absence of peripheral blood eosinophilia or other eosinophilic disorders.

PMID:
42509291
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.